Implication of protein tyrosine phosphatase SHP-1 in cancer-related signaling pathways.

Abstract

The altered expression of SHP-1 (SH2 domain-containing protein tyrosine phosphatase) as a consequence of promoter hypermethylation or mutations has evidently been linked to cancer development. The notion of being a cancer drug target is conceivable as SHP-1 negatively regulates cell cycle and inflammatory pathways which are an inevitable part of oncogenic transformation. In the present review, we try to critically analyze the role of SHP-1 in cancer progression via regulating the above mentioned pathways with the major emphasis on cell cycle components and JAK/STAT pathway, commencing with the SHP-1 biology in immune cell signaling. Lastly, we have provided the future directions for researchers to encourage SHP-1 as a prognostic marker and curative target for this debilitating disease called as cancer.

• Authors: Yadhu Sharma, Altaf Ahmad, Samina Bashir, Asif Elahi, Farah Khan
• Journal: Future oncology (London, England) (Future Oncol) Vol. 12 Issue 10 Pg. 1287-98 (May 2016) ISSN: 1744-8301 [Electronic] England
• PMID: 26987952 (Publication Type: Journal Article, Review)

Chemical References

• PTPN6 protein, human
• Protein Tyrosine Phosphatase, Non-Receptor Type 6

Topics

• Animals
• Disease Progression
• Humans
• Neoplasms (metabolism, pathology)
• Protein Tyrosine Phosphatase, Non-Receptor Type 6 (metabolism)
• Signal Transduction (physiology)